1
|
Loeber S. MRI Characteristics of Primary Brain Tumors and Advanced Diagnostic Imaging Techniques. Vet Clin North Am Small Anim Pract 2024:S0195-5616(24)00058-5. [PMID: 39244440 DOI: 10.1016/j.cvsm.2024.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2024]
Abstract
Extensive descriptions of MRI characteristics of canine and feline brain tumors allow for relatively accurate lesion detection, discrimination, and presumptive diagnosis on MRI. Ambiguous and overlapping MRI features between brain lesion and tumor as well as tumor types is a limitation that necessitates histopathology for final diagnosis, which is often not available antemortem. Non-invasive advanced diagnostic imaging techniques continue to be developed to enhance sensitivity and specificity for brain tumor diagnosis on MRI in dogs and cats.
Collapse
Affiliation(s)
- Samantha Loeber
- Department of Surgical Sciences, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA.
| |
Collapse
|
2
|
Loeber S. Brain MRI Protocol and Systematic Approach to Interpretation of Brain Tumors on MRI. Vet Clin North Am Small Anim Pract 2024:S0195-5616(24)00057-3. [PMID: 39244441 DOI: 10.1016/j.cvsm.2024.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/09/2024]
Abstract
MRI plays an integral role in the diagnosis of brain tumors in dogs and cats. Optimized image acquisition protocols in addition to a systematic approach to brain tumor evaluation on MRI using imaging characteristic interpretation criteria may allow for enhanced lesion detection, accurate presumptive diagnoses, and formulation of a prioritized differential diagnosis list.
Collapse
Affiliation(s)
- Samantha Loeber
- Department of Surgical Sciences, University of Wisconsin-Madison, 2015 Linden Drive, Madison, WI 53706, USA.
| |
Collapse
|
3
|
Carrera-Justiz S. Introduction and Summary of Diagnosis and Treatment of Brain Tumors in Dogs and Cats. Vet Clin North Am Small Anim Pract 2024:S0195-5616(24)00056-1. [PMID: 39227252 DOI: 10.1016/j.cvsm.2024.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/05/2024]
Abstract
Meningiomas are the most common tumor type in the brain in dogs and cats, and survival times are much higher for cats than dogs. Glioma is much more common in the dog, and median survival time is poor without definitive therapy. No recommendations currently exist for treatment of glioma in dogs, and there is ongoing research as the dog is a valid spontaneous model for the human equivalent disease. Other intracranial tumor types like lymphoma and histiocytic sarcoma do occur, though at a much lower frequency.
Collapse
Affiliation(s)
- Sheila Carrera-Justiz
- Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, PO Box 100126, Gainesville, FL 32610, USA.
| |
Collapse
|
4
|
Cahill JA, Smith LA, Gottipati S, Torabi TS, Graim K. Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers. Annu Rev Biomed Data Sci 2024; 7:107-129. [PMID: 38648188 PMCID: PMC11343685 DOI: 10.1146/annurev-biodatasci-102423-111936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Abstract
Dogs are humanity's oldest friend, the first species we domesticated 20,000-40,000 years ago. In this unequaled collaboration, dogs have inadvertently but serendipitously been molded into a potent human cancer model. Unlike many common model species, dogs are raised in the same environment as humans and present with spontaneous tumors with human-like comorbidities, immunocompetency, and heterogeneity. In breast, bladder, blood, and several pediatric cancers, in-depth profiling of dog and human tumors has established the benefits of the dog model. In addition to this clinical and molecular similarity, veterinary studies indicate that domestic dogs have relatively high tumor incidence rates. As a result, there are a plethora of data for analysis, the statistical power of which is bolstered by substantial breed-specific variability. As such, dog tumors provide a unique opportunity to interrogate the molecular factors underpinning cancer and facilitate the modeling of new therapeutic targets. This review discusses the emerging field of comparative oncology, how it complements human and rodent cancer studies, and where challenges remain, given the rapid proliferation of genomic resources. Increasingly, it appears that human's best friend is becoming an irreplaceable component of oncology research.
Collapse
Affiliation(s)
- James A Cahill
- University of Florida Genetics Institute, University of Florida, Gainesville, Florida, USA;
- Department of Environmental Engineering Sciences, University of Florida, Gainesville, Florida, USA
| | - Leslie A Smith
- Department of Computer and Information Science and Engineering, University of Florida, Gainesville, Florida, USA
| | - Soumya Gottipati
- Department of Computer Science, Princeton University, Princeton, New Jersey, USA
| | - Tina Salehi Torabi
- Department of Computer and Information Science and Engineering, University of Florida, Gainesville, Florida, USA
| | - Kiley Graim
- Department of Computer and Information Science and Engineering, University of Florida, Gainesville, Florida, USA
- University of Florida Health Cancer Center, University of Florida, Gainesville, Florida, USA
- University of Florida Genetics Institute, University of Florida, Gainesville, Florida, USA;
| |
Collapse
|
5
|
Molín J, José-López R, Ramírez GA, Pumarola M. Immunohistochemical Expression of PTEN in Canine Gliomas. Animals (Basel) 2024; 14:2115. [PMID: 39061577 PMCID: PMC11273977 DOI: 10.3390/ani14142115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2024] [Revised: 07/14/2024] [Accepted: 07/16/2024] [Indexed: 07/28/2024] Open
Abstract
Phosphatase and tensin homolog (PTEN) is a critical tumor suppressor gene with a vital role in regulating cell proliferation, migration, and survival. The loss of PTEN function, either by genetic alterations or decreased protein expression, is frequent in human gliomas and has been correlated with tumor progression, grade, therapeutic resistance, and decreased overall survival in patients with glioma. While different genetic mutations in PTEN gene have been occasionally reported in canine gliomas, no alterations in protein expression have been reported. This study investigates the immunohistochemical expression of PTEN in canine gliomas to evaluate possible alterations, as those reported in human gliomas. Immunohistochemical PTEN expression and pattern distribution were analyzed in 37 spontaneous canine gliomas. Among gliomas, 52.6% cases showed high PTEN expression and 48.6% displayed reduced (13.5%) or highly reduced (35.1%) immunopositivity. Most oligodendrogliomas showed high expression (73.7%), while the majority of astrocytomas (69.2%) showed a reduced or highly reduced expression. A reduced PTEN expression was mostly associated with a heterogeneous loss of PTEN immunopositivity. These observations are in line with those reported in human gliomas and provide a rationale for future studies regarding abnormalities in PTEN expression and PI3K/Akt/mTor pathway in canine gliomas, to evaluate its prognostic and therapeutic implications.
Collapse
Affiliation(s)
- Jéssica Molín
- Departament Ciència Animal, Campus Agroalimentari, Forestal i Veterinari, Universitat de Lleida, 25198 Lleida, Spain;
| | - Roberto José-López
- Division of Small Animal Clinical Sciences, School of Biodiversity, One Health and Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK;
- Neurology and Neurosurgery Service, Southfields Veterinary Specialists, Part of Linnaeus Veterinary Ltd., Basildon SS14 3AP, UK
| | - Gustavo A. Ramírez
- Departament Ciència Animal, Campus Agroalimentari, Forestal i Veterinari, Universitat de Lleida, 25198 Lleida, Spain;
| | - Martí Pumarola
- Unitat de Patologia Murina i Comparada, Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain;
| |
Collapse
|
6
|
dos Santos EC, Summers BA, Elbert JA, Miller DM, Rissi DR. Canine glioma in the first year of life: 5 cases. J Vet Diagn Invest 2024; 36:579-582. [PMID: 38561905 PMCID: PMC11185125 DOI: 10.1177/10406387241242733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024] Open
Abstract
Most canine gliomas occur in adult and aged dogs, and reports in puppies < 12-mo-old are exceedingly rare. Here we describe the occurrence of gliomas in 5 dogs ≤ 12-mo-old. The affected patients (4 males, 1 female) were 3-12-mo-old (x̄ = 6.6-mo-old). None of the dogs were brachycephalic. Clinical signs consisted of dullness (2 cases), seizures (2 cases), vestibular signs, and deafness (1 case each). All patients were euthanized. Grossly, neoplasms were pale-tan or red, soft masses in the telencephalon (4 cases) or gelatinous leptomeningeal thickening in the brain and spinal cord (1 case). Neoplasms were classified as astrocytomas (3 cases) and oligodendrogliomas (2 cases) based on histology or histology and IHC. Our findings confirm that, while exceptionally rare, canine gliomas occur in the first year of life, and are clinically, morphologically, and immunohistochemically similar to gliomas in adult and aged dogs.
Collapse
Affiliation(s)
- Esdras C. dos Santos
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Brian A. Summers
- Melbourne Veterinary School, University of Melbourne, Werribee, Victoria, Australia
| | - Jessica A. Elbert
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Doris M. Miller
- Athens Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Daniel R. Rissi
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
- Athens Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| |
Collapse
|
7
|
Espino L, Miño N. Common Neurologic Diseases in Geriatric Dogs. Animals (Basel) 2024; 14:1753. [PMID: 38929372 PMCID: PMC11200570 DOI: 10.3390/ani14121753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2024] [Revised: 05/28/2024] [Accepted: 06/05/2024] [Indexed: 06/28/2024] Open
Abstract
The increase in the canine geriatric population means that veterinarians are more often confronted with diseases that are more prevalent in patients in this age group. As in other organ systems, degenerative, neoplastic, and vascular diseases are the most prevalent neurologic disorders in older dogs. A neurological disease in an older dog poses a challenge for the clinician due to the presence of concomitant diseases and age-related changes that make it difficult to interpret the neurological examination. In addition, given the age of the patients, some owners do not allow advanced imaging tests, and it is necessary to establish the most likely presumptive diagnosis to initiate treatment. Although many of these diseases can cause clinical signs that can be very upsetting, some of them can be managed with symptomatic therapy and have a good prognosis, such as idiopathic vestibular syndrome. Moreover, advances in and the greater availability of therapeutic options such as surgery and radiation therapy may increase survival and quality of life in diseases with a more serious prognosis, such as tumours. The aim of this review is to summarize the clinical presentation, diagnosis, and treatment of the more frequent diseases affecting the central nervous systems of geriatric dogs.
Collapse
Affiliation(s)
- Luciano Espino
- Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultad de Veterinaria de Lugo, Universidad de Santiago de Compostela, 27002 Lugo, Spain;
| | | |
Collapse
|
8
|
Sun B, Lu W, Yu W, Tian Y, Wang P. Prevalence and risk factors of early postoperative seizures in patients with glioma: A protocol for meta-analysis and systematic review. PLoS One 2024; 19:e0301443. [PMID: 38574171 PMCID: PMC10994364 DOI: 10.1371/journal.pone.0301443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Accepted: 03/13/2024] [Indexed: 04/06/2024] Open
Abstract
INTRODUCTION Early postoperative seizures has been the most common clinical expression in gliomas; however, the incidence and risk factors for early postoperative seizures in gliomas are more controversial. This protocol describes a systematic review and meta-analysis to clarify the prevalence and risk factors of early postoperative seizures in patients with glioma. METHODS AND ANALYSIS Searches will be conducted on CNKI, WanFang, VIP, PubMed, Embase, Cochrane Library databases and Web of Science for the period from database inception to December 31st, 2023. Case-control and cohort studies of the incidence and risk factors for early postoperative seizures in all gliomas will be included. The primary outcome will be incidence, risk factors. Newcastle-Ottawa Scale was used for quality evaluation. Review of article screening, extracting data and risk of bias assessment will be repeated by two independent reviewers. RESULT This study will provide evidence for the risk factors and incidence of early postoperative seizures in patients with glioma. CONCLUSION Our study will provide evidence for the prevention of early postoperative seizures in glioma patients. TRAIL REGISTRATION This protocol was registered in PROSPERO and registration number is CRD42023415658.
Collapse
Affiliation(s)
- Bo Sun
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Wenpeng Lu
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Wangyang Yu
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Ye Tian
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Peng Wang
- Department of Neurosurgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, China
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| |
Collapse
|
9
|
May JL, Garcia-Mora J, Edwards M, Rossmeisl JH. An Illustrated Scoping Review of the Magnetic Resonance Imaging Characteristics of Canine and Feline Brain Tumors. Animals (Basel) 2024; 14:1044. [PMID: 38612283 PMCID: PMC11010916 DOI: 10.3390/ani14071044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 03/25/2024] [Accepted: 03/27/2024] [Indexed: 04/14/2024] Open
Abstract
Magnetic resonance imaging (MRI) is used pervasively in veterinary practice for the antemortem diagnosis of intracranial tumors. Here, we provide an illustrated summary of the published MRI features of primary and secondary intracranial tumors of dogs and cats, following PRISMA scoping review guidelines. The PubMed and Web of Science databases were searched for relevant records, and input from stakeholders was solicited to select data for extraction. Sixty-seven studies of moderate to low-level evidence quality describing the MRI features of pathologically confirmed canine and feline brain tumors met inclusion criteria. Considerable variability in data inclusion and reporting, as well as low case numbers, prohibited comparative data analyses. Available data support a holistic MRI approach incorporating lesion number, location within the brain, shape, intrinsic signal appearances on multiparametric sequences, patterns of contrast enhancement, and associated secondary changes in the brain to prioritize differential imaging diagnoses, and often allows for accurate presumptive diagnosis of common intracranial tumors. Quantitative MRI techniques show promise for improving discrimination of neoplastic from non-neoplastic brain lesions, as well as differentiating brain tumor types and grades, but sample size limitations will likely remain a significant practical obstacle to the design of robustly powered radiomic studies. For many brain tumor variants, particularly in cats, there remains a need for standardized studies that correlate clinicopathologic and neuroimaging data.
Collapse
Affiliation(s)
- James L. May
- Veterinary and Comparative Neuro-Oncology Laboratory, Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA; (J.L.M.); (J.G.-M.)
| | - Josefa Garcia-Mora
- Veterinary and Comparative Neuro-Oncology Laboratory, Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA; (J.L.M.); (J.G.-M.)
| | - Michael Edwards
- Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA;
| | - John H. Rossmeisl
- Veterinary and Comparative Neuro-Oncology Laboratory, Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA; (J.L.M.); (J.G.-M.)
| |
Collapse
|
10
|
Åsbjer E, Hedhammar Å, Engdahl K. Awareness, experiences, and opinions by owners, breeders, show judges, and veterinarians on canine Brachycephalic Obstructive Airway Syndrome (BOAS). Canine Med Genet 2024; 11:3. [PMID: 38459530 PMCID: PMC10924362 DOI: 10.1186/s40575-024-00137-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 01/31/2024] [Indexed: 03/10/2024] Open
Abstract
BACKGROUND Exaggerated brachycephalic features have been highlighted over the last decade by their profound effect on the health and welfare of the affected dogs. The term brachycephalic obstructive airway syndrome (BOAS) was launched in the early 2000s and has received worldwide attention and awareness. At the same time, the popularity of brachycephalic dogs increased. This study aimed to reveal the awareness and experiences of health issues related to the physical appearance of brachycephalic breeds and compare perceptions and opinions on how to counteract these issues by various stakeholders (dog owners, veterinarians, dog breeders, and show judges) by performing an online survey. RESULTS Altogether, 1602 owners, 1551 breeders, 118 show judges, and 557 veterinarians participated. Awareness and experiences of conformation-related health issues were common among all stakeholder groups. Most participants agreed fully or partly that health issues related to conformity threaten the health of brachycephalic breeds; that the measures taken so far are positive; and that guidelines on the appearance of a dog should be based on knowledge regarding health issues related to physical appearance. A disagreement was noted on further measures to be taken and the importance of adhering to a breed standard. CONCLUSIONS All stakeholders were aware of health issues related to the appearance of brachycephalic dogs, but had variable personal experiences of these issues. Most participants agreed fully or partly that health issues related to conformity threaten the health of brachycephalic breeds, and that attention to these issues and measures taken so far are positive. However, there is a disagreement on further actions to be taken and the importance of adhering to a breed standard. These findings could be used to understand and bridge the gap in opinions between stakeholders and to refine methods to influence the health of dogs with exaggerated brachycephalic features.
Collapse
Affiliation(s)
- Elina Åsbjer
- Department of Applied Animal Science and Welfare, Swedish Centre for Animal Welfare, Swedish University of Agricultural Sciences, PO Box 7054, 750 07, Uppsala, Sweden.
| | - Åke Hedhammar
- Department of Clinical Sciences, Small Animal Medicine, Swedish University of Agricultural Sciences, PO Box 7054, 750 07, Uppsala, Sweden
| | - Karolina Engdahl
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, PO Box 7054, 750 07, Uppsala, Sweden
| |
Collapse
|
11
|
Koehler JW, Miller AD, Rissi DR. Effects of autolysis and prolonged formalin fixation on histomorphology and immunohistochemistry of normal canine brain tissue: an experimental study. J Vet Diagn Invest 2024; 36:169-176. [PMID: 38212877 DOI: 10.1177/10406387231220649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2024] Open
Abstract
CNS tumor diagnosis in dogs often relies on immunohistochemistry (IHC) given similar histologic features among tumors. Most CNS tissue samples encountered by diagnostic pathologists are collected during autopsy, and postmortem specimens can be susceptible to autolysis and prolonged formalin fixation, both of which have the potential to influence IHC results and interpretation. Here we evaluated the effects of experimentally controlled autolysis induced by delayed tissue fixation (sections of brain held for 2, 4, 8, 12, 24, 48, and 72 h in 0.9% NaCl at either room temperature or 37°C prior to fixation) as well as the effects of prolonged formalin fixation times (1 wk, 1 mo, 2 mo) on a panel of 8 IHC markers (CNPase, GFAP, Iba1, OLIG2, PGP9.5, MAP2, NeuN, synaptophysin) relevant to brain tumor diagnosis. Prolonged fixation of up to 2 mo had no detrimental effect on any immunomarker except NeuN, which had reduced immunolabeling intensity. Delayed fixation led to autolytic changes as expected, on a gradient of severity corresponding to increased time in saline prior to fixation. Several immunomarkers should be used with caution (CNPase, OLIG2) or avoided entirely (MAP2, NeuN) in markedly autolyzed brain and brain tumor tissues. Our results suggest that autolysis has minimal effect on most immunomarkers, but that advanced autolysis may cause a loss of specificity for GFAP, MAP2, and PGP9.5, a loss of intensity of CNPase and OLIG2, and loss of labeling with MAP2 and NeuN. Prolonged fixation affected only NeuN, with mildly decreased intensity.
Collapse
Affiliation(s)
- Jennifer W Koehler
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, USA
| | - Andrew D Miller
- Department of Population Medicine and Diagnostic Sciences, Section of Anatomic Pathology, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - Daniel R Rissi
- Athens Veterinary Diagnostic Laboratory, Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| |
Collapse
|
12
|
Trageser E, Martin T, Burdekin B, Hart C, Leary D, LaRue S, Boss MK. Efficacy of stereotactic radiation therapy for the treatment of confirmed or presumed canine glioma. Vet Comp Oncol 2023; 21:578-586. [PMID: 37423611 DOI: 10.1111/vco.12920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 06/12/2023] [Accepted: 06/13/2023] [Indexed: 07/11/2023]
Abstract
Intracranial gliomas are the second most common brain tumour in dogs. Radiation therapy provides a minimally invasive treatment option for this tumour type. Earlier publications reporting on the use of non-modulated radiation therapy suggested a poor prognosis for dogs with glioma, with median survival times ranging between 4 and 6 months; more recent literature utilizing stereotactic radiation therapy (SRT) demonstrates that the prognosis for canine gliomas may be more promising, with survival times closer to 12 months. A single institution retrospective study was performed between 2010 and 2020 investigating the outcomes of dogs with biopsy-confirmed glioma or a presumptive diagnosis of intra-cranial glioma based on MRI characteristics that were treated with SRT. Twenty-three client-owned dogs were included. Brachycephalic breeds were overrepresented, totalling 13 dogs (57%). SRT protocols included 16 Gy single fraction (n = 1, 4%), 18 Gy single fraction (n = 1, 4%), 24 Gy in 3 daily fractions (n = 20, 91%), or 27 Gy in four daily fractions (n = 1, 4%). Twenty-one dogs (91%) had improvement of their presenting clinical signs following SRT. Median overall survival time (MST) was 349 days (95% CI, 162-584). Median disease specific survival time was 413 days (95% CI, 217-717). When SRT is incorporated into the management plan for dogs with confirmed or presumed intracranial glioma, a median survival time of approximately 12 months may be achievable.
Collapse
Affiliation(s)
- Erin Trageser
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Tiffany Martin
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Braden Burdekin
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Cullen Hart
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Del Leary
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Susan LaRue
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| | - Mary-Keara Boss
- Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA
| |
Collapse
|
13
|
Reyes VAA, Howerth EW, Blas-Machado U, Platt SR, Pavarini SP, Castro LT, Church ME, Rissi DR. Glioma with cribriform plate involvement in 6 dogs. J Vet Diagn Invest 2023; 35:800-805. [PMID: 37608783 PMCID: PMC10621564 DOI: 10.1177/10406387231195291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/24/2023] Open
Abstract
Distinct patterns of local infiltration are a common feature of canine oligodendroglioma and astrocytoma, and typically involve the surrounding neuroparenchyma, ventricles, or leptomeninges. Infiltration of adjacent extraneural sites is rare and has not been well documented in veterinary medicine. Here we describe 6 canine gliomas with cribriform plate involvement (compression or infiltration) and caudal nasal invasion confirmed by neuroimaging, autopsy, and/or histology. All affected dogs were adults (9-12-y-old), and 3 were brachycephalic. Clinical signs were associated with the brain tumor, with no respiratory signs reported. Magnetic resonance imaging in 2 patients revealed a rostral intraparenchymal telencephalic mass with extension into the cribriform plate. All dogs were euthanized. Gross changes consisted of poorly demarcated, white or pale-yellow, soft, and, in oligodendrogliomas, gelatinous, intraparenchymal masses that expanded the rostral portions of the telencephalon and adhered firmly to the ethmoid bone and cribriform plate. Gliomas were classified as high-grade oligodendrogliomas (4 cases) and high-grade astrocytomas (2 cases) based on histology and immunohistochemistry for OLIG2 and GFAP. In all cases, there was evidence of cribriform plate invasion and, in one case, additional invasion of the caudal nasal cavity.
Collapse
Affiliation(s)
- Vicente A. A. Reyes
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Elizabeth W. Howerth
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Uriel Blas-Machado
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
- Athens Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Simon R. Platt
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Saulo P. Pavarini
- Department of Veterinary Pathology, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil
| | - Lucas T. Castro
- Department of Veterinary Pathology, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil
| | - Molly E. Church
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Daniel R. Rissi
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
- Athens Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| |
Collapse
|
14
|
José-López R. Chemotherapy for the treatment of intracranial glioma in dogs. Front Vet Sci 2023; 10:1273122. [PMID: 38026627 PMCID: PMC10643662 DOI: 10.3389/fvets.2023.1273122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2023] [Accepted: 10/06/2023] [Indexed: 12/01/2023] Open
Abstract
Gliomas are the second most common primary brain tumor in dogs and although they are associated with a poor prognosis, limited data are available relating to the efficacy of standard therapeutic options such as surgery, radiation and chemotherapy. Additionally, canine glioma is gaining relevance as a naturally occurring animal model that recapitulates human disease with fidelity. There is an intense comparative research drive to test new therapeutic approaches in dogs and assess if results translate efficiently into human clinical trials to improve the poor outcomes associated with the current standard-of-care. However, the paucity of data and controversy around most appropriate treatment for intracranial gliomas in dogs make comparisons among modalities troublesome. To further inform therapeutic decision-making, client discussion, and future studies evaluating treatment responses, the outcomes of 127 dogs with intracranial glioma, either presumed (n = 49) or histologically confirmed (n = 78), that received chemotherapy as leading or adjuvant treatment are reviewed here. This review highlights the status of current chemotherapeutic approaches to intracranial gliomas in dogs, most notably temozolomide and lomustine; areas of novel treatment currently in development, and difficulties to consensuate and compare different study observations. Finally, suggestions are made to facilitate evidence-based research in the field of canine glioma therapeutics.
Collapse
Affiliation(s)
- Roberto José-López
- Hamilton Specialist Referrals – IVC Evidensia, High Wycombe, United Kingdom
| |
Collapse
|
15
|
TAKAHASHI T, SHIOZAWA H, ISHIZAKI T, OKADA K, KONDO H. Anaplastic oligodendroglioma with nasal invasion and systemic metastasis in a dog. J Vet Med Sci 2023; 85:1052-1056. [PMID: 37558495 PMCID: PMC10600530 DOI: 10.1292/jvms.23-0136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 07/26/2023] [Indexed: 08/11/2023] Open
Abstract
An 11-year-old spayed female French bulldog was referred on suspicion of nasal tumor. Anaplastic oligodendroglioma in the olfactory bulb that was suspected to have invaded the nasal cavity was diagnosed from imaging and histopathology. Metastasis to cervical lymph nodes was suspected, with no other metastases identified. The brain-to-nasal lesion and lymph nodes were treated with hypo-fractionated radiation therapy. Nasal congestion soon resolved. About 3 months later, follow-up computed tomography revealed multiple hepatic and splenic masses, which were cytologically suspected as metastatic oligodendroglioma. Nimustine, followed by toceranib phosphate, seemed to have no effect, and the dog died on day 167. Postmortem examination revealed the primary tumor disappearance and systemic metastases. Canine oligodendroglioma can grow outside the cranial vault, and systemically metastasize.
Collapse
Affiliation(s)
- Tomoko TAKAHASHI
- Department of Veterinary Medicine, College of Bioresource
Sciences, Nihon University, Kanagawa, Japan
| | - Hitoshi SHIOZAWA
- Department of Veterinary Medicine, College of Bioresource
Sciences, Nihon University, Kanagawa, Japan
| | | | | | - Hirotaka KONDO
- Department of Veterinary Medicine, College of Bioresource
Sciences, Nihon University, Kanagawa, Japan
| |
Collapse
|
16
|
Schrock MS, Zalenski AA, Tallman MM, Kollin L, Bratasz A, Weeks G, Miller MA, Sweeney CN, Pluhar GE, Olin MR, Kisseberth WC, Bentley RT, Dickinson PJ, York D, Webb A, Wang X, Moore S, Venere M, Summers MK. Establishment and characterization of two novel patient-derived lines from canine high-grade glioma. Vet Comp Oncol 2023; 21:492-502. [PMID: 37254642 PMCID: PMC10524959 DOI: 10.1111/vco.12912] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/30/2023] [Accepted: 05/12/2023] [Indexed: 06/01/2023]
Abstract
High-grade glioma is an aggressive cancer that occurs naturally in pet dogs. Canine high-grade glioma (cHGG) is treated with radiation, chemotherapy or surgery, but has no curative treatment. Within the past eight years, there have been advances in our imaging and histopathology standards as well as genetic charactereization of cHGG. However, there are only three cHGG cell lines publicly available, all of which were derived from astrocytoma and established using methods involving expansion of tumour cells in vitro on plastic dishes. In order to provide more clinically relevant cell lines for studying cHGG in vitro, the goal of this study was to establish cHGG patient-derived lines, whereby cancer cells are expanded in vivo by injecting cells into immunocompromized laboratory mice. The cells are then harvested from mice and used for in vitro studies. This method is the standard in the human field and has been shown to minimize the acquisition of genetic alterations and gene expression changes from the original tumour. Through a multi-institutional collaboration, we describe our methods for establishing two novel cHGG patient-derived lines, Boo-HA and Mo-HO, from a high-grade astrocytoma and a high-grade oligodendroglioma, respectively. We compare our novel lines to G06-A, J3T-Bg, and SDT-3G (traditional cHGG cell lines) in terms of proliferation and sensitivity to radiation. We also perform whole genome sequencing and identify an NF1 truncating mutation in Mo-HO. We report the characterization and availability of these novel patient-derived lines for use by the veterinary community.
Collapse
Affiliation(s)
- Morgan S Schrock
- Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH, USA
| | - Abigail A Zalenski
- Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH, USA
- Neuroscience Graduate Program, The Ohio State University, Columbus, OH, USA
| | - Miranda M Tallman
- Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH, USA
- Biomedical Sciences Graduate, Program The Ohio State University Columbus, OH, USA
| | - Luke Kollin
- Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH, USA
| | - Anna Bratasz
- Small Animal Imaging Core, The Ohio State University, Columbus, OH, USA
| | - Griffin Weeks
- Small Animal Imaging Core, The Ohio State University, Columbus, OH, USA
| | - Margaret A Miller
- Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA
| | - Courtney N Sweeney
- Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA
| | - G Elizabeth Pluhar
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota, USA
| | - Michael R Olin
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
| | - William C. Kisseberth
- Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, USA
| | - R Timothy Bentley
- Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN, USA
| | - Peter J Dickinson
- Department of Surgical and Radiological Sciences, UC Davis School of Veterinary Medicine, The University of California, Davis, CA, USA
| | - Daniel York
- Department of Surgical and Radiological Sciences, UC Davis School of Veterinary Medicine, The University of California, Davis, CA, USA
| | - Amy Webb
- Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA
| | - Xu Wang
- Department of Pathobiology, Auburn University, Auburn, AL, USA
| | - Sarah Moore
- Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, OH, USA
| | - Monica Venere
- Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH, USA
| | - Matthew K Summers
- Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
17
|
Garcia‐Mora J, Parker RL, Cecere T, Robertson JL, Rossmeisl JH. The T2-FLAIR mismatch sign as an imaging biomarker for oligodendrogliomas in dogs. J Vet Intern Med 2023; 37:1447-1454. [PMID: 37246729 PMCID: PMC10365042 DOI: 10.1111/jvim.16749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 05/09/2023] [Indexed: 05/30/2023] Open
Abstract
BACKGROUND In humans, the T2-weighted (T2W)-fluid-attenuated inversion recovery (FLAIR) mismatch sign (T2FMM) is a specific imaging biomarker for the isocitrate dehydrogenase 1 (IDH1)-mutated, 1p/19q non-codeleted low-grade astrocytomas (LGA). The T2FMM is characterized by a homogeneous hyperintense T2W signal and a hypointense signal with a hyperintense peripheral rim on FLAIR sequences. In gliomas in dogs, the T2FMM has not been described. HYPOTHESES/OBJECTIVES In dogs with focal intra-axial brain lesions, T2FMM will discriminate gliomas from other lesions. The T2FMM will be associated with the LGA phenotype and presence of microcysts on histopathology. Interobserver agreement for T2FMM magnetic resonance imaging (MRI) features will be high. ANIMALS One hundred eighty-six dogs with histopathologically diagnosed focal intra-axial lesions on brain MRI including oligodendrogliomas (n = 90), astrocytomas (n = 47), undefined gliomas (n = 9), cerebrovascular accidents (n = 33), and inflammatory lesions (n = 7). METHODS Two blinded raters evaluated the 186 MRI studies and identified cases with the T2FMM. Histopathologic and immunohistochemical slides of T2FMM cases were evaluated for morphologic features and IDH1-mutations and compared to cases without the T2FMM. Gene expression analyses were performed on a subset of oligodendrogliomas (n = 10) with and without T2FMM. RESULTS The T2FMM was identified in 14/186 (8%) of MRI studies, and all dogs with T2FMM had oligodendrogliomas (n = 12 low-grade [LGO], n = 2 high-grade [HGO]; P < .001). Microcystic change was significantly associated with the T2FMM (P < .00001). In oligodendrogliomas with T2FMM, IDH1-mutations or specific differentially expressed genes were not identified. CONCLUSION AND CLINICAL IMPORTANCE The T2FMM can be readily identified on routinely obtained MRI sequences. It is a specific biomarker for oligodendroglioma in dogs, and was significantly associated with non-enhancing LGO.
Collapse
Affiliation(s)
- Josefa Garcia‐Mora
- Department of Small Animal Clinical Sciences and Animal Cancer Care and Research CenterVirginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
- Veterinary and Comparative Neuro‐Oncology Laboratory, Virginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
| | - Rell L. Parker
- Department of Small Animal Clinical Sciences and Animal Cancer Care and Research CenterVirginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
| | - Thomas Cecere
- Department of Biomedical Sciences & PathobiologyVirginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
| | - John L. Robertson
- Veterinary and Comparative Neuro‐Oncology Laboratory, Virginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
- School of Biomedical Engineering and Sciences, Virginia Tech‐Wake Forest UniversityBlacksburgVirginiaUSA
- Comprehensive Cancer Center and Brain Tumor Center of Excellence, Wake Forest School of MedicineWinston‐SalemNorth CarolinaUSA
| | - John H. Rossmeisl
- Department of Small Animal Clinical Sciences and Animal Cancer Care and Research CenterVirginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
- Veterinary and Comparative Neuro‐Oncology Laboratory, Virginia‐Maryland College of Veterinary Medicine, Virginia TechBlacksburgVirginiaUSA
- School of Biomedical Engineering and Sciences, Virginia Tech‐Wake Forest UniversityBlacksburgVirginiaUSA
- Comprehensive Cancer Center and Brain Tumor Center of Excellence, Wake Forest School of MedicineWinston‐SalemNorth CarolinaUSA
| |
Collapse
|
18
|
Barge P, Oevermann A, Maiolini A, Durand A. Machine learning predicts histologic type and grade of canine gliomas based on MRI texture analysis. Vet Radiol Ultrasound 2023. [PMID: 37133981 DOI: 10.1111/vru.13242] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 03/16/2023] [Accepted: 03/21/2023] [Indexed: 05/04/2023] Open
Abstract
Conventional MRI features of canine gliomas subtypes and grades significantly overlap. Texture analysis (TA) quantifies image texture based on spatial arrangement of pixel intensities. Machine learning (ML) models based on MRI-TA demonstrate high accuracy in predicting brain tumor types and grades in human medicine. The aim of this retrospective, diagnostic accuracy study was to investigate the accuracy of ML-based MRI-TA in predicting canine gliomas histologic types and grades. Dogs with histopathological diagnosis of intracranial glioma and available brain MRI were included. Tumors were manually segmented across their entire volume in enhancing part, non-enhancing part, and peri-tumoral vasogenic edema in T2-weighted (T2w), T1-weighted (T1w), FLAIR, and T1w postcontrast sequences. Texture features were extracted and fed into three ML classifiers. Classifiers' performance was assessed using a leave-one-out cross-validation approach. Multiclass and binary models were built to predict histologic types (oligodendroglioma vs. astrocytoma vs. oligoastrocytoma) and grades (high vs. low), respectively. Thirty-eight dogs with a total of 40 masses were included. Machine learning classifiers had an average accuracy of 77% for discriminating tumor types and of 75.6% for predicting high-grade gliomas. The support vector machine classifier had an accuracy of up to 94% for predicting tumor types and up to 87% for predicting high-grade gliomas. The most discriminative texture features of tumor types and grades appeared related to the peri-tumoral edema in T1w images and to the non-enhancing part of the tumor in T2w images, respectively. In conclusion, ML-based MRI-TA has the potential to discriminate intracranial canine gliomas types and grades.
Collapse
Affiliation(s)
- Pablo Barge
- Division of Clinical Radiology, Department of Clinical Veterinary Science, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Anna Oevermann
- Division of Neurological Sciences, Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Arianna Maiolini
- Division of Clinical Neurology, Department of Clinical Veterinary Science, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Alexane Durand
- Division of Clinical Radiology, Department of Clinical Veterinary Science, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
19
|
Oh JH, Cho JY. Comparative oncology: overcoming human cancer through companion animal studies. Exp Mol Med 2023; 55:725-734. [PMID: 37009802 PMCID: PMC10167357 DOI: 10.1038/s12276-023-00977-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 01/20/2023] [Accepted: 01/25/2023] [Indexed: 04/04/2023] Open
Abstract
Comparative oncology is a field of study that has been recently adopted for studying cancer and developing cancer therapies. Companion animals such as dogs can be used to evaluate novel biomarkers or anticancer targets before clinical translation. Thus, the value of canine models is increasing, and numerous studies have been conducted to analyze similarities and differences between many types of spontaneously occurring cancers in canines and humans. A growing number of canine cancer models as well as research-grade reagents for these models are becoming available, leading to substantial growth in comparative oncology research spanning from basic science to clinical trials. In this review, we summarize comparative oncology studies that have been conducted on the molecular landscape of various canine cancers and highlight the importance of the integration of comparative biology into cancer research.
Collapse
Affiliation(s)
- Ji Hoon Oh
- Department of Biochemistry, Brain Korea 21 Project and Research Institute for Veterinary Science, Seoul National University College of Veterinary Medicine, Seoul, 08826, Republic of Korea
- Comparative Medicine Disease Research Center, Seoul National University, Seoul, 08826, Republic of Korea
| | - Je-Yoel Cho
- Department of Biochemistry, Brain Korea 21 Project and Research Institute for Veterinary Science, Seoul National University College of Veterinary Medicine, Seoul, 08826, Republic of Korea.
- Comparative Medicine Disease Research Center, Seoul National University, Seoul, 08826, Republic of Korea.
| |
Collapse
|
20
|
Tolbert A, Weyna A, Sakamoto K, Perlini M, Platt S. Magnetic resonance imaging and pathological characteristics of
Cladophialophora
encephalitis in a young dog. VETERINARY RECORD CASE REPORTS 2023. [DOI: 10.1002/vrc2.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Affiliation(s)
- Alexis Tolbert
- University of Georgia Veterinary Teaching Hospital Athens Georgia USA
| | - Alisia Weyna
- University of Georgia Veterinary Teaching Hospital Athens Georgia USA
| | - Kaori Sakamoto
- University of Georgia Veterinary Teaching Hospital Athens Georgia USA
| | - Michael Perlini
- University of Georgia Veterinary Teaching Hospital Athens Georgia USA
| | - Simon Platt
- University of Georgia Veterinary Teaching Hospital Athens Georgia USA
| |
Collapse
|
21
|
Hanael E, Baruch S, Chai O, Lishitsky L, Blum T, Rapoport K, Ruggeri M, Aizenberg Z, Peery D, Meyerhoff N, Volk HA, De Decker S, Tipold A, Baumgaertner W, Friedman A, Shamir M. Quantitative analysis of magnetic resonance images for characterization of blood-brain barrier dysfunction in dogs with brain tumors. J Vet Intern Med 2023; 37:606-617. [PMID: 36847997 DOI: 10.1111/jvim.16654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Accepted: 02/03/2023] [Indexed: 03/01/2023] Open
Abstract
BACKGROUND Blood-brain barrier (BBB) permeability can be assessed quantitatively using advanced imaging analysis. HYPOTHESIS/OBJECTIVES Quantification and characterization of blood-brain barrier dysfunction (BBBD) patterns in dogs with brain tumors can provide useful information about tumor biology and assist in distinguishing between gliomas and meningiomas. ANIMALS Seventy-eight hospitalized dogs with brain tumors and 12 control dogs without brain tumors. METHODS In a 2-arm study, images from a prospective dynamic contrast-enhanced (DCE; n = 15) and a retrospective archived magnetic resonance imaging study (n = 63) were analyzed by DCE and subtraction enhancement analysis (SEA) to quantify BBB permeability in affected dogs relative to control dogs (n = 6 in each arm). For the SEA method, 2 ranges of postcontrast intensity differences, that is, high (HR) and low (LR), were evaluated as possible representations of 2 classes of BBB leakage. BBB score was calculated for each dog and was associated with clinical characteristics and tumor location and class. Permeability maps were generated, using the slope values (DCE) or intensity difference (SEA) of each voxel, and analyzed. RESULTS Distinctive patterns and distributions of BBBD were identified for intra- and extra-axial tumors. At a cutoff of 0.1, LR/HR BBB score ratio yielded a sensitivity of 80% and specificity of 100% in differentiating gliomas from meningiomas. CONCLUSIONS AND CLINICAL IMPORTANCE Blood-brain barrier dysfunction quantification using advanced imaging analyses has the potential to be used for assessment of brain tumor characteristics and behavior and, particularly, to help differentiating gliomas from meningiomas.
Collapse
Affiliation(s)
- Erez Hanael
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Shelly Baruch
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Orit Chai
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Liron Lishitsky
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Tal Blum
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Kira Rapoport
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Marco Ruggeri
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Zahi Aizenberg
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Dana Peery
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| | - Nina Meyerhoff
- School of Veterinary Medicine Hannover, Small Animal Medicine and Surgery, Hannover, Germany
| | - Holger Andreas Volk
- School of Veterinary Medicine Hannover, Small Animal Medicine and Surgery, Hannover, Germany
| | - Steven De Decker
- Department of Clinical Sciences, Royal Veterinary College, University of London, Hertfordshire, UK
| | - Andrea Tipold
- School of Veterinary Medicine Hannover, Small Animal Medicine and Surgery, Hannover, Germany
| | - Wolfgang Baumgaertner
- School of Veterinary Medicine Hannover, Small Animal Medicine and Surgery, Hannover, Germany
| | - Alon Friedman
- Faculty of Medicine, Department of Medical Neuroscience Halifax, Dalhousie University, Nova Scotia, Canada.,Departments of Physiology and Cell Biology, Brain, and Cognitive Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Merav Shamir
- The Koret School of Veterinary Medicine, Neurology and Neurosurgery, Hebrew University of Jerusalem, Reehovot, Israel
| |
Collapse
|
22
|
Mortier JR, Maddox TW, Blackwood L, La Fontaine MD, Busoni V. Dynamic contrast-enhanced computed tomography perfusion parameters of canine suspected brain tumors at baseline and during radiotherapy might be different depending on tumor location but not associated with survival. Front Vet Sci 2023; 10:1179762. [PMID: 37187932 PMCID: PMC10175699 DOI: 10.3389/fvets.2023.1179762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2023] [Accepted: 04/10/2023] [Indexed: 05/17/2023] Open
Abstract
Introduction Treatment of brain tumors in dogs can be associated with significant morbidity and reliable prognostic factors are lacking. Dynamic contrast-enhanced computed tomography (DCECT) can be used to assess tumor perfusion. The objectives of this study were to assess perfusion parameters and change in size of suspected brain tumors before and during radiotherapy (RT) depending on their location and find a potential correlation with survival. Methods Seventeen client-owned dogs with suspected brain tumors were prospectively recruited. All dogs had a baseline DCECT to assess mass size, blood volume (BV), blood flow (BF), and transit time (TT). Twelve dogs had a repeat DCECT after 12 Gy of megavoltage RT. Survival times were calculated. Results Intra-axial masses had lower BF (p = 0.005) and BV (p < 0.001) than extra-axial masses but not than pituitary masses. Pituitary masses had lower BF (p = 0.001) and BV (p = 0.004) than extra-axial masses. The volume of the mass was positively associated with TT (p = 0.001) but not with BF and BV. Intra-axial masses showed a more marked decrease in size than extra-axial and pituitary masses during RT (p = 0.022 for length, p = 0.05 for height). Extra-axial masses showed a greater decrease in BF (p = 0.011) and BV (p = 0.012) during RT than pituitary masses and intra-axial masses. Heavier dogs had a shorter survival time (p = 0.011). Perfusion parameters were not correlated with survival. Conclusion DCECT perfusion parameters and change in size of brain masses during RT might be different based on the location of the mass.
Collapse
Affiliation(s)
- Jeremy R. Mortier
- Small Animal Teaching Hospital, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Neston, United Kingdom
- Diagnostic Imaging Section, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium
- *Correspondence: Jeremy R. Mortier,
| | - Thomas W. Maddox
- Small Animal Teaching Hospital, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Neston, United Kingdom
| | - Laura Blackwood
- Small Animal Teaching Hospital, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Neston, United Kingdom
| | | | - Valeria Busoni
- Diagnostic Imaging Section, Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium
| |
Collapse
|
23
|
Cloquell A, Mateo I, Gambera S, Pumarola M, Alemany R, García-Castro J, Perisé-Barrios AJ. Systemic cellular viroimmunotherapy for canine high-grade gliomas. J Immunother Cancer 2022; 10:jitc-2022-005669. [PMID: 36600663 PMCID: PMC9772696 DOI: 10.1136/jitc-2022-005669] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2022] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Oncolytic viruses constitute a growing field of interest, both in human and veterinary oncology, given that they are particularly helpful for treating non-surgical tumors and disseminated cancer, such as high-grade gliomas. Companion dogs present malignant gliomas with biological, genetic, phenotypic, immunological, and clinical similarities to human gliomas. These features favor comparative approaches, leading to the treatment of canine oncological patients to achieve translational applications to the human clinic. The systemic administration of oncolytic viruses presents a challenge due to their limitations in effectively targeting tumors and metastases. Therefore, the aim of this study is to evaluate the safety and antitumor activity of a virotherapy used in spontaneous canine tumors. METHODS Ten dogs with high-grade rostrotentorial gliomas underwent weekly systemic endovenous cellular virotherapy with dCelyvir (canine mesenchymal stem cells infected with the canine oncolytic adenovirus ICOCAV17) for 8 weeks. Efficacy was determined in seven dogs according to the Response Assessment in Veterinary Neuro-Oncology criteria considering clinical status and MRI measurements. Medical history, physical and neurological examinations, and vaccination status were evaluated prior to and during follow-up. Safety was evaluated by physical examinations and hematological and biochemical changes in peripheral blood. Immune populations were analyzed by flow cytometry in peripheral blood and by gene expression and immunohistochemistry in the tumor microenvironment. RESULTS The treatment was well tolerated and major adverse effects were not observed. Two dogs had partial responses (76% and 86% reduction in tumor size), and 3/7 showed stable disease. ICOCAV17 was detected in peripheral blood in nine dogs, and a correlation between the ICOCAV17 particles and anti-canine adenovirus (CAV) antibodies was observed. ICOCAV17 was detected in 3/9 tumor tissues after necropsies. Regarding tumor-infiltrating lymphocytes, the dogs with disease stabilization and partial response tended to have reduced memory B-cell infiltration and increased monocyte/macrophage lineage cells. CONCLUSIONS These findings indicate that dCelyvir is safe and presents efficacy in canine rostrotentorial high-grade gliomas. These data are relevant to the ongoing phase Ib regulated human clinical trial that is administering this virotherapy to children, adolescents, and young adults with diffuse pontine glioma. Celyvir should be further explored as a treatment in veterinary and human neuro-oncology.
Collapse
Affiliation(s)
- Ana Cloquell
- Servicio de Neurología, Hospital Clínico Veterinario, Universidad Alfonso X el Sabio, Villanueva de la Cañada, Spain
| | - Isidro Mateo
- Servicio de Neurología, Hospital Clínico Veterinario, Universidad Alfonso X el Sabio, Villanueva de la Cañada, Spain,Servicio de Neurología, Hospital Veterinario VETSIA, Leganés, Spain
| | - Stefano Gambera
- Unidad de Biotecnología Celular, Instituto de Salud Carlos III, Madrid, Spain,Molecular Genetics of Angiogenesis Group, Spanish National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - Martí Pumarola
- Unitat de Patologia Murina i Comparada (UPMiC), Departament de Medicina i Cirurgia Animals, Facultat de Veterinaria, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Ramon Alemany
- IDIBELL, Institut Català d'Oncologia, Barcelona, Spain
| | | | - Ana Judith Perisé-Barrios
- Unidad de Investigación Biomédica (UIB-UAX), Universidad Alfonso X el Sabio, Villanueva de la Cañada, Spain
| |
Collapse
|
24
|
Ammons DT, Guth A, Rozental AJ, Kurihara J, Marolf AJ, Chow L, Griffin JF, Makii R, MacQuiddy B, Boss MK, Regan DP, Frank C, McGrath S, Packer RA, Dow S. Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses. CANCER RESEARCH COMMUNICATIONS 2022; 2:1657-1667. [PMID: 36644324 PMCID: PMC9835010 DOI: 10.1158/2767-9764.crc-22-0388] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 11/09/2022] [Accepted: 11/14/2022] [Indexed: 11/17/2022]
Abstract
Purpose Malignant gliomas have a highly immune suppressive tumor microenvironment (TME) which renders them largely unresponsive to conventional therapeutics. Therefore, the present study evaluated a therapeutic protocol designed overcome the immune barrier by combining myeloid cell targeted immunotherapy with tumor vaccination. Experimental Design We utilized a spontaneously occurring canine glioma model to investigate an oral TME modifying immunotherapy in conjunction with cancer stem cell (CSC) vaccination. Dogs were treated daily with losartan (monocyte migration inhibitor) and propranolol (myeloid-derived suppressor cell depleting agent) plus anti-CSC vaccination on a bi-weekly then monthly schedule. Tumor volume was monitored by MRI and correlated with patient immune responses. Results Ten dogs with histologically confirmed gliomas were enrolled into a prospective, open-label clinical trial to evaluate the immunotherapy protocol. Partial tumor regression was observed in 2 dogs, while 6 dogs experienced stable disease, for an overall clinical benefit rate of 80%. Overall survival times (median = 351 days) and progression-free intervals (median = 163 days) were comparable to prior studies evaluating surgical debulking followed by immunotherapy. Dogs with detectable anti-CSC antibody responses had an increased overall survival time relative to dogs that did not generate antibody responses (vaccine responder MST = 500 days; vaccine non-responder MST = 218 days; p = 0.02). Conclusions These findings suggest that combining myeloid cell targeted oral immunotherapy with tumor vaccination can generate objective tumor responses, even in the absence of conventional therapy. Overall, this approach has promise as a readily implemented therapeutic strategy for use in brain cancer patients.
Collapse
Affiliation(s)
- Dylan T. Ammons
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
| | - Amanda Guth
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - Aaron J. Rozental
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - Jade Kurihara
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - Angela J. Marolf
- Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado
| | - Lyndah Chow
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - John F. Griffin
- Department of Large Animal Clinical Sciences, Texas A&M University, College Station, Texas
| | - Rebecca Makii
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
| | - Brittany MacQuiddy
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - Mary-Keara Boss
- Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado
| | - Daniel P. Regan
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
| | - Chad Frank
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
| | - Stephanie McGrath
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - Rebecca A. Packer
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| | - Steven Dow
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado
- Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado
| |
Collapse
|
25
|
Amphimaque B, Durand A, Oevermann A, Vidondo B, Schweizer D. Grading of oligodendroglioma in dogs based on magnetic resonance imaging. Vet Med (Auckl) 2022; 36:2104-2112. [DOI: 10.1111/jvim.16519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 08/02/2022] [Indexed: 11/13/2022]
Affiliation(s)
- Bénédicte Amphimaque
- Division of Clinical Radiology, Department of Clinical Veterinary Medicine, Vetsuisse Faculty University of Bern Bern Switzerland
| | - Alexane Durand
- Division of Clinical Radiology, Department of Clinical Veterinary Medicine, Vetsuisse Faculty University of Bern Bern Switzerland
| | - Anna Oevermann
- Division of Neurological Sciences, Department of Clinical Research and Veterinary Public Health, Vetsuisse‐Faculty University of Bern Bern Switzerland
| | - Beatriz Vidondo
- Veterinary Public Health Institute, Vetsuisse‐Faculty University of Bern Bern Switzerland
| | - Daniela Schweizer
- Division of Clinical Radiology, Department of Clinical Veterinary Medicine, Vetsuisse Faculty University of Bern Bern Switzerland
| |
Collapse
|
26
|
Muller K, Kim E, Lebowitz A, Daverio H. A High Grade Astrocytoma with Pilocytic Morphology in a 5-Month-Old American Bulldog. Vet Sci 2022; 9:vetsci9100580. [PMID: 36288193 PMCID: PMC9609793 DOI: 10.3390/vetsci9100580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Revised: 10/16/2022] [Accepted: 10/17/2022] [Indexed: 11/06/2022] Open
Abstract
Simple Summary Dogs are valuable models for spontaneous intracranial neoplasia in humans. The most common intracranial neoplasm in dogs is meningioma, followed by glioma and choroid plexus tumors. Pilocytic astrocytoma (PA) is a form of glioma and is a common childhood and adolescent tumor in humans. There have been two previous reports of PA in dogs. These cases were both adult dogs and the clinical and imaging features were not described. This report describes a 23-week-old female intact American Bulldog with a 2-week progressive history of neurologic dysfunction. Magnetic resonance imaging (MRI) revealed a large hemorrhagic mass that was confirmed on post-mortem examination to be a high-grade astrocytoma with pilocytic morphology. This case is the first to report a high-grade astrocytoma with pilocytic morphology in a juvenile dog. Abstract A 23-week-old female intact American Bulldog was presented for a two-week history of progressive circling to the right, twitching, and altered mentation. Magnetic resonance imaging (MRI) revealed a non-contrast enhancing hemorrhagic mass centered in the right thalamus with concurrent subdural and intraventricular hemorrhage. Post-mortem histologic examination of the brain confirmed a mass centered on the thalamus with histomorphologic features consistent with a high-grade astrocytoma with pilocytic morphology. To the authors’ knowledge, the present case is the first to report clinical and imaging characteristics of a high-grade astrocytoma with pilocytic morphology in a young dog.
Collapse
|
27
|
The Microbeam Insert at the White Beam Beamline P61A at the Synchrotron PETRA III/DESY: A New Tool for High Dose Rate Irradiation Research. Cancers (Basel) 2022; 14:cancers14205137. [PMID: 36291920 PMCID: PMC9600877 DOI: 10.3390/cancers14205137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 10/04/2022] [Accepted: 10/16/2022] [Indexed: 11/16/2022] Open
Abstract
Simple Summary The excellent preservation of normal tissue function after high dose rate radiotherapy has been shown in pre-clinical studies. Normal tissue in the tumor environment is well preserved even after target doses of several hundred Gy while reliably destroying the tumor cells. These results have triggered the establishment of appropriate research structures at the synchrotron PETRA III on the DESY campus in Hamburg, Germany. Dose rates of hundreds of Gy/s can be achieved, compared to 6–20 Gy/min in clinical radiotherapy. We describe the design, development, key parameters, and first use of a mobile insert for high dose rate radiotherapy research, a new research instrument at P61A, the first polychromatic beamline of PETRA III. The data obtained at the end station P61A will support the international interdisciplinary effort to improve radiotherapy concepts for patients with malignant tumors that are considered radioresistant with the currently established clinical radiotherapy techniques. Abstract High dose rate radiotherapies such as FLASH and microbeam radiotherapy (MRT) both have developed to the stage of first veterinary studies within the last decade. With the development of a new research tool for high dose rate radiotherapy at the end station P61A of the synchrotron beamline P61 on the DESY campus in Hamburg, we increased the research capacity in this field to speed up the translation of the radiotherapy techniques which are still experimental, from bench to bedside. At P61, dose rates of several hundred Gy/s can be delivered. Compared to dedicated biomedical beamlines, the beam width available for MRT experiments is a very restrictive factor. We developed two model systems specifically to suit these specific technical parameters and tested them in a first set of experiments.
Collapse
|
28
|
Franson A, McClellan BL, Varela ML, Comba A, Syed MF, Banerjee K, Zhu Z, Gonzalez N, Candolfi M, Lowenstein P, Castro MG. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. Front Med (Lausanne) 2022; 9:966458. [PMID: 36186781 PMCID: PMC9515652 DOI: 10.3389/fmed.2022.966458] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 08/22/2022] [Indexed: 01/07/2023] Open
Abstract
The preclinical and clinical development of novel immunotherapies for the treatment of central nervous system (CNS) tumors is advancing at a rapid pace. High-grade gliomas (HGG) are aggressive tumors with poor prognoses in both adult and pediatric patients, and innovative and effective therapies are greatly needed. The use of cytotoxic chemotherapies has marginally improved survival in some HGG patient populations. Although several challenges exist for the successful development of immunotherapies for CNS tumors, recent insights into the genetic alterations that define the pathogenesis of HGG and their direct effects on the tumor microenvironment (TME) may allow for a more refined and targeted therapeutic approach. This review will focus on the TME in HGG, the genetic drivers frequently found in these tumors and their effect on the TME, the development of immunotherapy for HGG, and the practical challenges in clinical trials employing immunotherapy for HGG. Herein, we will discuss broadly the TME and immunotherapy development in HGG, with a specific focus on glioblastoma multiforme (GBM) as well as additional discussion in the context of the pediatric HGG diagnoses of diffuse midline glioma (DMG) and diffuse hemispheric glioma (DHG).
Collapse
Affiliation(s)
- Andrea Franson
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Brandon L. McClellan
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Immunology Graduate Program, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Maria Luisa Varela
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Andrea Comba
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Mohammad Faisal Syed
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Kaushik Banerjee
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Ziwen Zhu
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
| | - Nazareno Gonzalez
- Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Marianela Candolfi
- Instituto de Investigaciones Biomédicas (INBIOMED, UBA-CONICET), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Pedro Lowenstein
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Department of Biomedical Engineering, University of Michigan Medical School, Ann Arbor, MI, United States
- Biosciences Initiative in Brain Cancer, Biointerface Institute, University of Michigan, Ann Arbor, MI, United States
| | - Maria Graciela Castro
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, United States
- Biosciences Initiative in Brain Cancer, Biointerface Institute, University of Michigan, Ann Arbor, MI, United States
| |
Collapse
|
29
|
Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas. Vet Sci 2022; 9:vetsci9080427. [PMID: 36006342 PMCID: PMC9414206 DOI: 10.3390/vetsci9080427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2022] [Revised: 07/03/2022] [Accepted: 08/01/2022] [Indexed: 11/30/2022] Open
Abstract
Simple Summary Infiltrative brain tumours are common in dogs. Although different treatments have been used, such as surgery, radiotherapy, chemotherapy, or combinations, guidelines for the most effective management are lacking. In this study, we report the effect of combining surgery and chemotherapy on the survival of 14 dogs with infiltrative gliomas. Four dogs were operated on two or three times to remove the tumors, and only one of these dogs died shortly after the second surgery. All tolerated the surgery with minimal or no deterioration, and all were euthanized between 6 months to 2 years after diagnosis due to tumour progression. To conclude, surgery and chemotherapy, although not curative, can prolong survival in dogs with infiltrative brain tumours. This information may help future research into the most appropriate treatment for this debilitating condition. Abstract Intracranial gliomas are associated with a poor prognosis, and the most appropriate treatment is yet to be defined. The objectives of this retrospective study are to report the time to progression and survival times of a group of dogs with histologically confirmed intracranial gliomas treated with surgical debulking and adjuvant temozolomide chemotherapy. All cases treated in a single referral veterinary hospital from 2014 to 2021 were reviewed. Inclusion criteria comprised a histopathological diagnosis of intracranial glioma, adjunctive chemotherapy, and follow-up until death. Cases were excluded if the owner declined chemotherapy or there was insufficient follow-up information in the clinical records. Fourteen client-owned dogs were included with a median time to progression (MTP) of 156 days (95% CI 133–320 days) and median survival time (MST) of 240 days (95% CI 149–465 days). Temozolomide was the first-line adjuvant chemotherapy but changed to another chemotherapy agent (lomustine, toceranib phosphate, or melphalan) when tumour relapse was either suspected by clinical signs or confirmed by advanced imaging. Of the fourteen dogs, three underwent two surgical resections and one, three surgeries. Survival times (ST) were 241, 428, and 468 days for three dogs treated twice surgically and 780 days for the dog treated surgically three times. Survival times for dogs operated once was 181 days. One case was euthanized after developing aspiration pneumonia, and all other cases after progression of clinical signs due to suspected or confirmed tumour relapse. In conclusion, the results of this study suggest that debulking surgery and adjuvant chemotherapy are well-tolerated options in dogs with intracranial gliomas in which surgery is a possibility and should be considered a potential treatment option. Repeated surgery may be considered for selected cases.
Collapse
|
30
|
Park J, Lee D, Yun T, Koo Y, Chae Y, Kim H, Yang MP, Kang BT. Evaluation of the blood neutrophil-to-lymphocyte ratio as a biomarker for meningoencephalitis of unknown etiology in dogs. J Vet Intern Med 2022; 36:1719-1725. [PMID: 35929724 PMCID: PMC9511057 DOI: 10.1111/jvim.16512] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Accepted: 07/19/2022] [Indexed: 12/14/2022] Open
Abstract
Background The neutrophil‐to‐lymphocyte ratio (NLR) has been identified as a biomarker in several inflammatory and autoimmune diseases. Multiple sclerosis (MS) has been found to be associated with changes in the NLR in humans. Objectives To examine the diagnostic value of the NLR in meningoencephalitis of unknown etiology (MUE) in dogs. Animals Thirty‐eight MUE dogs, 20 hydrocephalic dogs, 10 brain tumor (BT) dogs, 32 idiopathic epilepsy (IE) dogs, and 41 healthy dogs. Methods Retrospective study. Medical records were reviewed to identify dogs with a diagnosis of neurologic disease. The NLR was determined in all dogs. Results The median NLR was significantly higher in MUE dogs (6.08) than in healthy (1.78, P < .001), IE (2.50, P < .05), and hydrocephalic dogs (1.79, P < .05). The area under the receiver operating characteristic curve of the NLR for differentiation between MUE and healthy dogs was 0.96, and between the MUE dogs and dogs with other forebrain diseases was 0.86. An optimal cutoff of 4.16 for the NLR had a sensitivity of 71.1% and specificity of 83.9% to differentiate the MUE dogs from the dogs with other forebrain diseases. Conclusions and Clinical Importance The NLR could be a biomarker for diagnosing MUE and distinguishing it from other intracranial diseases in dogs.
Collapse
Affiliation(s)
- Jooyoung Park
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Dohee Lee
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Taesik Yun
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Yoonhoi Koo
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Yeon Chae
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Hakhyun Kim
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Mhan-Pyo Yang
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| | - Byeong-Teck Kang
- Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea
| |
Collapse
|
31
|
Jaekel F, Bräuer-Krisch E, Bartzsch S, Laissue J, Blattmann H, Scholz M, Soloviova J, Hildebrandt G, Schültke E. Microbeam Irradiation as a Simultaneously Integrated Boost in a Conventional Whole-Brain Radiotherapy Protocol. Int J Mol Sci 2022; 23:ijms23158319. [PMID: 35955454 PMCID: PMC9368396 DOI: 10.3390/ijms23158319] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Revised: 07/20/2022] [Accepted: 07/25/2022] [Indexed: 02/05/2023] Open
Abstract
Microbeam radiotherapy (MRT), an experimental high-dose rate concept with spatial fractionation at the micrometre range, has shown a high therapeutic potential as well as good preservation of normal tissue function in pre-clinical studies. We investigated the suitability of MRT as a simultaneously integrated boost (SIB) in conventional whole-brain irradiation (WBRT). A 174 Gy MRT SIB was administered with an array of quasi-parallel, 50 µm wide microbeams spaced at a centre-to-centre distance of 400 µm either on the first or last day of a 5 × 4 Gy radiotherapy schedule in healthy adult C57 BL/6J mice and in F98 glioma cell cultures. The animals were observed for signs of intracranial pressure and focal neurologic signs. Colony counts were conducted in F98 glioma cell cultures. No signs of acute adverse effects were observed in any of the irradiated animals within 3 days after the last irradiation fraction. The tumoricidal effect on F98 cell in vitro was higher when the MRT boost was delivered on the first day of the irradiation course, as opposed to the last day. Therefore, the MRT SIB should be integrated into a clinical radiotherapy schedule as early as possible.
Collapse
Affiliation(s)
- Felix Jaekel
- Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany; (F.J.); (M.S.); (J.S.); (G.H.)
| | - Elke Bräuer-Krisch
- Biomedical Beamline ID 17, European Synchrotron Radiation Facility (ESRF), 38043 Grenoble, France;
| | - Stefan Bartzsch
- Department of Radiooncology, Technical University of Munich, 81675 Munich, Germany;
- Institute for Radiation Medicine, Helmholtz Center Munich, 85764 Munich, Germany
| | - Jean Laissue
- Institute of Anatomy, University of Bern, 3012 Bern, Switzerland;
| | | | - Marten Scholz
- Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany; (F.J.); (M.S.); (J.S.); (G.H.)
| | - Julia Soloviova
- Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany; (F.J.); (M.S.); (J.S.); (G.H.)
- Department of Paediatric Surgery, Leipzig University Medical Centre, 04103 Leipzig, Germany
| | - Guido Hildebrandt
- Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany; (F.J.); (M.S.); (J.S.); (G.H.)
| | - Elisabeth Schültke
- Department of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany; (F.J.); (M.S.); (J.S.); (G.H.)
- Correspondence:
| |
Collapse
|
32
|
Al-Nadaf S, Peacott-Ricardos KS, Dickinson PJ, Rebhun RB, York D. Expression and therapeutic targeting of BMI1 in canine gliomas. Vet Comp Oncol 2022; 20:871-880. [PMID: 35833892 DOI: 10.1111/vco.12852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 06/27/2022] [Accepted: 06/28/2022] [Indexed: 12/01/2022]
Abstract
The BMI1 proto-oncogene, polycomb ring finger protein (BMI1) is a key component of the epigenetic polycomb repressor complex 1, and has been associated with aggressive behavior and chemotherapeutic resistance in various malignances including human gliomas. Similar to humans, spontaneous canine gliomas carry a poor prognosis with limited therapeutic options. BMI1 expression and the effects of BMI1 inhibition have not been evaluated in canine gliomas. Here, we demonstrate that BMI1 is highly expressed in canine gliomas. Although increased BMI1 protein expression correlated with higher glioma grade in western blot assays, this correlation was not observed in a larger sample set using immunohistochemical analysis. The BMI1 inhibitor, PTC-209, suppressed BMI1 expression in established canine glioma cell lines and resulted in antiproliferative activity when used alone and in combination with chemotherapeutic agents. PTC-209 targeting of BMI1 activated the RB pathway through downregulation of total and phosphorylated RB, independent of INK4A/ARF signaling, likely through BMI1-inhibition mediated upregulation of p21. These data support the rationale for targeting of BMI1 signaling and the use of canine glioma as a translational therapeutic model for human disease. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Sami Al-Nadaf
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA
| | - Kyle S Peacott-Ricardos
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA
| | - Peter J Dickinson
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA
| | - Robert B Rebhun
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA
| | - Daniel York
- Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA, USA
| |
Collapse
|
33
|
Cardy TJA, Jewth‐Ahuja D, Crawford AH. Perceptions and attitudes towards companion animal brain banking in pet owners: A UK pilot study. Vet Rec Open 2022; 9:e36. [PMID: 35663272 PMCID: PMC9142818 DOI: 10.1002/vro2.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 03/29/2022] [Accepted: 04/25/2022] [Indexed: 11/08/2022] Open
Abstract
Background Detailed analysis of archived brain tissue is fundamental to advancing the understanding of neurological disease. The development of the UK Brain Bank Network (UBBN) has provided an invaluable resource to facilitate such research in the human medical field. Similar resources are needed in veterinary medicine. However, collection and archiving of companion animal brain tissue is a potentially sensitive area for pet owners and veterinary professionals. Methods Using an online survey, we aimed to study pet owners’ perceptions of brain banking. The survey included information on respondents, their views on organ donation, the UBBN and the Royal Veterinary College's Companion Animal Brain Bank (RVC CABB). Results In total 185 respondents were included. The use of brain tissue from pets for research was supported by 87% of respondents, and 66% of respondents felt that they were highly likely or likely to donate their pet's brain tissue to a CABB. Furthermore, 94% felt that more information on tissue banking in companion animals should be readily available. Conclusions We found that the perceptions of companion animal brain banking were positive in our respondents. Open dialogue and clear information provision on the process and benefits of the CABB could enhance awareness and thus facilitate brain donation for translational research.
Collapse
Affiliation(s)
- Thomas J. A. Cardy
- Cave Veterinary Specialists, George's Farm West Buckland Wellington UK
- Clinical Science and Services Royal Veterinary College AL9 7TA, North Mymms, Hatfield Herts UK
| | - Daniel Jewth‐Ahuja
- Clinical Science and Services Royal Veterinary College AL9 7TA, North Mymms, Hatfield Herts UK
| | - Abbe H. Crawford
- Clinical Science and Services Royal Veterinary College AL9 7TA, North Mymms, Hatfield Herts UK
| |
Collapse
|
34
|
Pons-Sorolla M, Dominguez E, Czopowicz M, Suñol A, Maeso Ordás C, Morales Moliner C, Pérez Soteras M, Montoliu P. Clinical and Magnetic Resonance Imaging (MRI) Features, Tumour Localisation, and Survival of Dogs with Presumptive Brain Gliomas. Vet Sci 2022; 9:257. [PMID: 35737309 PMCID: PMC9230849 DOI: 10.3390/vetsci9060257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 05/20/2022] [Accepted: 05/24/2022] [Indexed: 02/01/2023] Open
Abstract
Brain gliomas are common tumours diagnosed in dogs. However, limited information is available on the clinical features and overall survival time (OS) in dogs receiving palliative treatment. The aim of this study was to evaluate possible associations between presenting complaint, tumour localisation, Magnetic Resonance Imaging (MRI) features, survival times, and reason for the death of dogs with suspected intracranial glioma treated palliatively. Sixty dogs from a single institution were retrospectively included (from September 2017 to December 2021). Dogs were included if a presumptive diagnosis of brain glioma was obtained based on an MRI scan and medical history. French Bulldogs were overrepresented (40/60); 46 out of 60 dogs (77%) presented due to epileptic seizures (ES) and in 25/60 dogs (42%), cluster seizures or status epilepticus were the first manifestation of the disease. Dogs with suspected gliomas located in the piriform lobe showed a higher probability of presenting due to epilepsy compared to dogs with glioma in other regions, and more frequently died or were euthanised because of increased ES. Magnetic Resonance Imaging (MRI) features differed between localisations. Fronto-olfactory tumours were more frequently, whereas piriform tumours were less frequently, classified as suspected high-grade glioma. The median survival time was 61 days. Dogs with contrast-enhancing suspected gliomas had significantly shorter OS. This study provides additional information on the clinical features and survival of dogs with suspected brain gliomas treated palliatively.
Collapse
Affiliation(s)
- Marta Pons-Sorolla
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| | - Elisabet Dominguez
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| | - Michał Czopowicz
- Division of Veterinary Epidemiology and Economics, Institute of Veterinary Medicine, Warsaw University of Life Sciences—SGGW, Nowoursynowska 159c, 02-776 Warsaw, Poland;
| | - Anna Suñol
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| | - Christian Maeso Ordás
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| | - Carles Morales Moliner
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| | - Marc Pérez Soteras
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| | - Patrícia Montoliu
- AniCura Ars Veterinaria Hospital Veterinari, Carrer dels Cavallers 37, 08034 Barcelona, Spain; (M.P.-S.); (E.D.); (A.S.); (C.M.O.); (C.M.M.); (M.P.S.)
| |
Collapse
|
35
|
Johnson PJ, Rivard BC, Wood JH, DiRubio ML, Henry JG, Miller AD. Relationship between histological tumor margins and magnetic resonance imaging signal intensities in brain neoplasia of dogs. J Vet Intern Med 2022; 36:1039-1048. [PMID: 35488504 PMCID: PMC9151476 DOI: 10.1111/jvim.16431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 04/04/2022] [Accepted: 04/12/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Intracranial neoplasia is relatively common in dogs and stereotactic radiotherapy, surgical debulking, or both, are the most successful treatment approaches. A key component of treatment planning involves delineating tumor margin on magnetic resonance imaging (MRI) examinations. How MRI signal intensity alterations relate to histological tumor margins is unknown. OBJECTIVES Directly compare histological brain sections to MRI sequence images and determine which sequence alteration best correlates with tumor margins. ANIMALS Five dogs with glioma, 4 dogs with histiocytic sarcoma, and 3 dogs with meningioma. METHODS Retrospective cohort study. Histological brain sections were registered to in vivo MRI scan images obtained within 7 days of necropsy. Margins of signal intensity alterations (T2-weighted, fluid-attenuating inversion recovery [FLAIR], T1-weighted and contrast enhancement) were compared directly to solid tumor and surgical margins identified on histology. Jacquard similarity metrics (JSM) and cross-sectional areas were calculated. RESULTS In glioma cases, margins drawn around T2-weighted hyperintensity were most similar to surgical margins (JSM, 0.66 ± 0.17) when compared to other sequences. In both meningioma (JSM, 0.57 ± 0.21) and histiocytic sarcoma (JSM, 0.75 ± 0.11) margins of contrast enhancement were most similar to surgical margins. CONCLUSIONS AND CLINICAL IMPORTANCE Signal intensities correspond to tumor margins for different tumor types and facilitate surgical and radiation therapy planning using MRI images.
Collapse
Affiliation(s)
- Philippa J Johnson
- Department of Clinical Sciences, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Benjamin C Rivard
- Department of Clinical Sciences, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Jonathan H Wood
- Department of Clinical Sciences, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Mattisen L DiRubio
- Department of Clinical Sciences, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Joshua G Henry
- Department of Clinical Sciences, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Andrew D Miller
- Department of Biomedical Sciences, Section of Anatomic Pathology, Cornell College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| |
Collapse
|
36
|
Mora JKG, Robertson J, Hsu FC, Shinn RL, Larson MM, Rylander CG, Whitlow CT, Debinski W, Davalos RV, B Daniel G, Rossmeisl JH. Comparison of linear and volumetric criteria for the determination of therapeutic response in dogs with intracranial gliomas. J Vet Intern Med 2022; 36:1066-1074. [PMID: 35274379 PMCID: PMC9151452 DOI: 10.1111/jvim.16406] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 03/02/2022] [Accepted: 03/02/2022] [Indexed: 11/29/2022] Open
Abstract
Background Brain tumor therapeutic responses can be quantified from magnetic resonance images (MRI) using 1‐ (1D) and 2‐dimensional (2D) linear and volumetric methods, but few studies in dogs compare these techniques. Hypotheses Linear methods will be obtained faster, but have less agreement than volumetric measurements. Therapeutic response agreement will be highest with the total T2W tumor volumetric (TTV) method. Therapeutic response at 6‐weeks will correlate with overall survival (OS). Animals Forty‐six dogs with intracranial gliomas. Methods Prospective study. Three raters measured tumors using 1D and 2D linear, TTV, and contrast‐enhancing volumetric (CEV) techniques on 143 brain MRI to determine agreement between methods, define therapeutic responses, and assess relations with OS. Results Raters performed 1D the fastest (2.9 ± 0.57 minutes) and CEV slowest (17.8 ± 6.2 minutes). Inter‐ and intraobserver agreements were excellent (intraclass correlations ≥.91) across methods. Correlations between linear (1D vs 2D; ρ > .91) and volumetric (TTV vs CEV; ρ > .73) methods were stronger than linear to volumetric comparisons (ρ range, .26‐.59). Incorporating clinical and imaging data resulted in fewer discordant therapeutic responses across methods. Dogs having partial tumor responses at 6 weeks had a lower death hazard than dogs with stable or progressive disease when assessed using 2D, CEV, and TTV (hazard ration 2.1; 95% confidence interval, 1.22‐3.63; P = .008). Conclusions and Clinical Importance One‐dimensional, 2D, CEV, and TTV are comparable for determining therapeutic response. Given the simplicity, universal applicability, and superior performance of the TTV, we recommend its use to standardize glioma therapeutic response criteria.
Collapse
Affiliation(s)
- Josefa Karina Garcia Mora
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - John Robertson
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - Fang-Chi Hsu
- Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
| | - Richard Levon Shinn
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - Martha M Larson
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - Christopher G Rylander
- Walker Department of Mechanical Engineering, University of Texas at Austin, Austin, Texas, USA
| | - Christopher T Whitlow
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - Waldemar Debinski
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - Rafael V Davalos
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - Gregory B Daniel
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - John H Rossmeisl
- Small Animal Clinical Sciences, VA-MD Regional College of Veterinary Medicine, Blacksburg, Virginia, USA
| |
Collapse
|
37
|
Santifort K, Van Soens I, Beukers M, Grinwis G, Lugt J, Mandigers P. Papillary meningioma with multifocal leptomeningeal spread in a dog. VETERINARY RECORD CASE REPORTS 2022. [DOI: 10.1002/vrc2.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Koen Santifort
- Evidensia Small Animal Hospital Arnhem Arnhem The Netherlands
- Evidensia Small Animal Hospital Hart van Brabant Waalwijk The Netherlands
| | - Iris Van Soens
- Evidensia Small Animal Hospital Hart van Brabant Waalwijk The Netherlands
| | - Martijn Beukers
- Evidensia Small Animal Hospital Hart van Brabant Waalwijk The Netherlands
- Focus Veterinary Imaging Utrecht The Netherlands
| | - Guy Grinwis
- Veterinary Pathology Diagnostic Centre Department of Biomolecular Health Sciences Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands
| | - Jaco Lugt
- IDEXX Europe Hoofddorp The Netherlands
| | - Paul Mandigers
- Evidensia Small Animal Hospital Arnhem Arnhem The Netherlands
- Department of Clinical Sciences of Companion Animals Faculty of Veterinary Medicine University of Utrecht Utrecht The Netherlands
| |
Collapse
|
38
|
Coppola G, Morris J, Gutierrez-Quintana R, Burnside S, José-López R. Comparison of response assessment in veterinary neuro-oncology and two volumetric neuroimaging methods to assess therapeutic brain tumour responses in veterinary patients. Vet Comp Oncol 2021; 20:404-415. [PMID: 34792828 DOI: 10.1111/vco.12786] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 11/11/2021] [Indexed: 12/13/2022]
Abstract
Standardized veterinary neuroimaging response assessment methods for brain tumours are lacking. Consequently, a response assessment in veterinary neuro-oncology (RAVNO) system which uses the sum product of orthogonal lesion diameters on 1-image section with the largest tumour area, has recently been proposed. In this retrospective study, 22 pre-treatment magnetic resonance imaging (MRI) studies from 18 dogs and four cats with suspected intracranial neoplasia were compared by a single observer to 32 post-treatment MRIs using the RAVNO system and two volumetric methods based on tumour margin or area delineation with HOROS and 3D Slicer software, respectively. Intra-observer variability was low, with no statistically significant differences in agreement index between methods (mean AI ± SD, 0.91 ± 0.06 for RAVNO; 0.86 ± 0.08 for HOROS; and 0.91 ± 0.05 for 3D slicer), indicating good reproducibility. Response assessments consisting of complete or partial responses, and stable or progressive disease, agreed in 23 out of 32 (72%) MRI evaluations using the three methods. The RAVNO system failed to identify changes in mass burden detected with volumetric methods in six cases. 3D Slicer differed from the other two methods in three cases involving cysts or necrotic tissue as it allowed for more accurate exclusion of these structures. The volumetric response assessment methods were more precise in determining changes in absolute tumour burden than RAVNO but were more time-consuming to use. Based on observed agreement between methods, low intra-observer variability and decreased time constraint, RAVNO might be a suitable response assessment method for the clinical setting.
Collapse
Affiliation(s)
- Giovanni Coppola
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Joanna Morris
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Rodrigo Gutierrez-Quintana
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Shona Burnside
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Roberto José-López
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| |
Collapse
|
39
|
Manzanedo‐Delgado A, Mason S, Pumarola M, Stabile F. Diagnostic imaging, treatment and outcome in a 14‐month‐old Dobermann with brainstem gemistocytic astrocytoma. VETERINARY RECORD CASE REPORTS 2021. [DOI: 10.1002/vrc2.202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
| | - Sarah Mason
- Department of Oncology and Radiology Southfields Veterinary Specialists Basildon UK
| | - Marti Pumarola
- Faculty of Veterinary Unit of Murine and Comparative Pathology (UPMiC) Autonomous University of Barcelona Bellaterra Barcelona Spain
| | - Fabio Stabile
- Department of Neurology/Neurosurgery Southfields Veterinary Specialists Basildon UK
| |
Collapse
|
40
|
José‐López R, Gutierrez‐Quintana R, de la Fuente C, Manzanilla EG, Suñol A, Pi Castro D, Añor S, Sánchez‐Masian D, Fernández‐Flores F, Ricci E, Marioni‐Henry K, Mascort J, Matiasek LA, Matiasek K, Brennan PM, Pumarola M. Clinical features, diagnosis, and survival analysis of dogs with glioma. J Vet Intern Med 2021; 35:1902-1917. [PMID: 34117807 PMCID: PMC8295679 DOI: 10.1111/jvim.16199] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 05/25/2021] [Accepted: 05/27/2021] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Gliomas in dogs remain poorly understood. OBJECTIVES To characterize the clinicopathologic findings, diagnostic imaging features and survival of a large sample of dogs with glioma using the Comparative Brain Tumor Consortium diagnostic classification. ANIMALS Ninety-one dogs with histopathological diagnosis of glioma. METHODS Multicentric retrospective case series. Signalment, clinicopathologic findings, diagnostic imaging characteristics, treatment, and outcome were used. Tumors were reclassified according to the new canine glioma diagnostic scheme. RESULTS No associations were found between clinicopathologic findings or survival and tumor type or grade. However, definitive treatments provided significantly (P = .03) improved median survival time (84 days; 95% confidence interval [CI], 45-190) compared to palliative treatment (26 days; 95% CI, 11-54). On magnetic resonance imaging (MRI), oligodendrogliomas were associated with smooth margins and T1-weighted hypointensity compared to astrocytomas (odds ratio [OR], 42.5; 95% CI, 2.42-744.97; P = .04; OR, 45.5; 95% CI, 5.78-333.33; P < .001, respectively) and undefined gliomas (OR, 84; 95% CI, 3.43-999.99; P = .02; OR, 32.3; 95% CI, 2.51-500.00; P = .008, respectively) and were more commonly in contact with the ventricles than astrocytomas (OR, 7.47; 95% CI, 1.03-53.95; P = .049). Tumor spread to neighboring brain structures was associated with high-grade glioma (OR, 6.02; 95% CI, 1.06-34.48; P = .04). CONCLUSIONS AND CLINICAL IMPORTANCE Dogs with gliomas have poor outcomes, but risk factors identified in survival analysis inform prognosis and the newly identified MRI characteristics could refine diagnosis of tumor type and grade.
Collapse
Affiliation(s)
- Roberto José‐López
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of GlasgowGlasgowUK
- Department of Animal Medicine and Surgery, Veterinary FacultyUniversitat Autònoma de BarcelonaBarcelonaSpain
| | - Rodrigo Gutierrez‐Quintana
- School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of GlasgowGlasgowUK
| | - Cristian de la Fuente
- Department of Animal Medicine and Surgery, Veterinary FacultyUniversitat Autònoma de BarcelonaBarcelonaSpain
| | - Edgar G. Manzanilla
- School of Veterinary Medicine, University College DublinDublinIreland
- TEAGASC, The Irish Food and Agriculture AuthorityCorkIreland
| | - Anna Suñol
- ARS VeterinariaBarcelonaSpain
- Present address:
Royal (Dick) School of Veterinary Studies, University of EdinburghEdinburghUK
| | - Dolors Pi Castro
- Department of Animal Medicine and Surgery, Veterinary FacultyUniversitat Autònoma de BarcelonaBarcelonaSpain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER‐BBN), Universitat Autònoma de BarcelonaBarcelonaSpain
- Present address:
Anicura Arvivet Hospital VeterinariBarcelonaSpain
| | - Sonia Añor
- Department of Animal Medicine and Surgery, Veterinary FacultyUniversitat Autònoma de BarcelonaBarcelonaSpain
| | - Daniel Sánchez‐Masian
- Institute of Veterinary Science, University of LiverpoolNestonUK
- Present address:
Anderson Moores Veterinary SpecialistsWinchesterUK
| | | | - Emanuele Ricci
- Institute of Veterinary Science, University of LiverpoolNestonUK
| | - Katia Marioni‐Henry
- Royal (Dick) School of Veterinary Studies and Roslin Institute, University of EdinburghEdinburghUK
| | | | - Lara A. Matiasek
- Tierklinik HaarHaarGermany
- Present address:
Anicura Small Animal ClinicBabenhausenGermany
| | - Kaspar Matiasek
- Centre for Clinical Veterinary Medicine, Ludwig‐Maximilians‐UniversitaetMunichGermany
| | - Paul M. Brennan
- Translational Neurosurgery, Centre for Clinical Brain Sciences, University of EdinburghEdinburghUK
| | - Martí Pumarola
- Department of Animal Medicine and Surgery, Veterinary FacultyUniversitat Autònoma de BarcelonaBarcelonaSpain
- Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER‐BBN), Universitat Autònoma de BarcelonaBarcelonaSpain
| |
Collapse
|